Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.42 |
| ▸ | CKS1B | P61024 | 2/20 | 0.42 |
| ▸ | SKP1 | P63208 | 2/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | ADK | P55263 | 1/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3402754 | 0.87 | MAP4K4 (0.43) | NR1H2MAP4K4DDB1CRBNCKS1B | |
| SCHEMBL15205695 | 0.87 | MAP4K4 (0.42) | NR1H2MAP4K4DDB1CRBNCKS1B | |
| SCHEMBL21360344 | 0.87 | ENPP2 (0.45) | NR1H2MAP4K4DDB1CRBNCKS1B | |
| SCHEMBL29978453 | 0.86 | HRH3 (0.45) | NR1H2MAP4K4DDB1CRBNCKS1B | |
| SCHEMBL28343832 | 0.86 | HRH3 (0.45) | NR1H2MAP4K4DDB1CRBNCKS1B | |
| SCHEMBL1583767 | 0.86 | GPR119 (0.46) | NR1H2MAP4K4DDB1CRBNGPR119 | |
| SCHEMBL2710989 | 0.84 | PANK3 (0.45) | MAP4K4GPR119ADK | |
| SCHEMBL265889 | 0.83 | MAP4K4 (0.60) | MAP4K4DDB1CRBNCKS1BSKP1 | |
| SCHEMBL29612182 | 0.83 | MAP4K4 (0.60) | MAP4K4DDB1CRBNCKS1BSKP1 | |
| SCHEMBL1583147 | 0.82 | GPR119 (0.58) | CKS1BSKP1SKP2GPR119SMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | NR1H2 4452/4885MAP4K4 990/4885DDB1 176/4885 |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, CCNE1 | NR1H2 3894/4885MAP4K4 1074/4885DDB1 290/4885 |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | NR1H2 3187/4885MAP4K4 54/4885DDB1 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.